Preparations of next generation monoclonal antibodies (issues and prospects)

The article provides the information on issues related to the clinical use of preparations of monoclonal antibodies (MAb), and the prospects for developing preparations based on modified MAbs. MAb preparations based on recombinant proteins show the consistency of physical and chemical properties as well as high specificity. New class of preparations based on MAbs show great potential of targeted therapeutic influence on important pathogenetic mechanisms of disease development. It has proved to be successful against severe chronic diseases such as autoimmune cancer, infectious and allergic diseases, as well as in transplantation for the treatment and prevention of transplant rejection. The development and manufacture of MAb preparations based on a whole immunoglobulin molecule, as well as preparations of modified antibodies with a specific set of functions associated with individual structural elements of the molecule is now possible due to genetic engineering and transgenic animals technologies. Preparations based on modified MAb can exist in

лекарственные препараты, моноклональные антитела, препараты модифицированных моноклональных антител, иммуноглобулин класса G, нежелательная иммуногенность, конъюгированные моноклональные антитела, технология генной инженерии, биотехнологические препараты

1. Kohler G., Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-7 [classical article]. Biotechnology 1992; (24): 524-6.

2. Ярилин А.А. Иммунология. М.: ГЭОТАР-Медиа; 2010.

3. Dillman R. Antibody therapy. Principles of cancer biotherapy. Ed. by R. Oldham, London: Kluwer Academic Publ.; 1998.

4. Roopenian D.C., Akilesh S. FcRn: the neonatal Fc receptor comes of age. Nat Rev Immunol. 2007; 7(9): 715-25.

5. Goebl N.A., Babbey C.M., Datta-Mannan A., Witcher D.R., Wroblewski V.J., Dunn K.W. Neonatal Fc Receptor mediates internalization of Fc in transfected human endothelial cells. Mol Biol Cell 2008; 19(12): 5490-505.

6. Насонов Е.Л., Каратеев А.Е., Клюквина Н.Г. Фармакотерапия. В кн.: Насонов Е.Л., Насонова В.А. Ревматология: национальное руководство. М.: ГЭОТАР-Медиа; 2008.

7. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993; 36(12), 1681-90.

8. Hanauer S.B., Sandborn W.J., Rutgeerts P., Fedorak R.N., Lukas M., Macintosh D., et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006; 130(2): 323-3; quiz 591.

9. Keystone E.C. Safety of biologic therapies - an update. J. Rheumatol. Suppl 2005; 74: 8-12.

10. Markham A., Lamb H.M. Infliximab: a review of its use in the management of rheumatoid arthritis. Drugs 2000; 59(6): 1341-59.

11. Моисеенко В.М. Возможности моноклональных антител в лечении злокачественных опухолей. Практическая онкология 2002; 3(4): 253-61.

12. Gutheil J. The promise of monoclonal antibodies for the therapy of cancer. Critical rev. Oncol. Hematology 2001; (38): 1-2.

13. Witzig T.E., Gordon L.I., Cabanillas F., Czuczman M.S., Emmanouilides C., Joyce R., et al. Randomized controlled trial of Yttrium-90-labelled Ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low grade, follicular or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002; 20(10): 2453-63.

14. Kaminski M.S., Zelenetz A.D., Press O.W., Saleh M., Leonard J., Fehrenbacher L., et al. Pivotal study of Iodine 131 tositumomab for chemotherapy refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001; 19(19): 3918-28.

15. Oratz R., Speyer J.L., Wernz J.C., Hochster H., Meyers M., Mischak R., et al. Antimelanoma monoclonal antibody-ricin A chain immunoconjugate (XMMME-001-RTA) plus cyclophosphamide in the treatment of metastatic malignant melanoma: results of a phase II trial. J. Biol. Response Mod. 1990; 9(4): 345-54.

16. Lynch T.J. Jr, Lambert J.M., Coral F., Shefner J., Wen P., Blattler W.A., et al. Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin. J. Clin. Oncol. 1997; 15(2): 723-34.

17. LeMaistre C.F., Rosen S., Frankel A., Kornfeld S., Saria E., Meneghetti C. Phase I trial of H65-RTA immunoconjugate in patients with cutaneous T-cell lymphoma. Blood 1991; 78(5): 1173-82.

18. Dillman R.O., Johnson D.E., Ogden J., Beidler D. Significance of antigen, drug, and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Mol. Biother. 1989; 1(5): 250-5.

19. Dillman R.O. Antibodies as cytotoxic therapy. J. Clin. Oncol. 1994; 12: 1497-515.

20. Tolcher A.W., Sugarman S., Gelmon K.A., Cohen R., Saleh M., Isaacs C., et al. Randomized phase II study of BR96-doxorubicin conjugate in patients with metastatic breast cancer. J. Clin. Oncol. 1999; 17(2): 478-84.

21. Stan A.C., Radu D.L., Casares S., Bona C.A., Brumeanu T.D. Antineoplastic efficacy of doxorubicin enzymatically assembled on galactose residues of monoclonal antibody specific for the carcinoembryonic antigen. Cancer 1999; 59(1): 115-21.

22. Baldwin R.W. Selective cytotoxicity against human tumour cells by a vindesine-monoclonal antibody conjugate. Br. J. Cancer 1983; 47: 43-9.

23. Барышников А.Ю., Оборотов Н.А. Иммунолипосомы - новое средство доставки лекарственных препаратов. Современная онкология 2001; 3(2): 3-7.

24. Rosenecker J., Zhang W., Hong K., Lausier J., Geppetti P., Yoshihara S., Papahadjopoulos D., et al. Increased liposome extravasation in selected tissues: effect of substance P. Proc. Natl Acad. Sci. USA 1996; 93( 14): 7236-41.

25. Kong G., Anyarambhatla G., Petros W.P., Braun R.D., et al. Efficacy of liposomes and hyperthermia in a human tumor xenograft model: importance of triggered drug release. Cancer Res. 2000; 60(24): 6950-7.

26. Papahadjopoulos D., Kilpotin D.B., Park J.W., Hong K., Shao Yi., Shalaby R., et al. Targeting of drugs to solid tumors using anti-HER2 immunoliposomes. J. Liposome Research 1998; 8(4): 425-42.

27. Dufresne I., Desormeaux A., Bestman-Smith J., Gourde P., Tremblay M.J., Bergeron M.G. Targeting lymph nodes with liposomes bearing anti-HLA-DR Fab’ fragments. Biochim. Biophys. Acta 1999; 1421(2): 284-94.

28. Bestman-Smith J., Gourde P., Desormeaux A., et al. Sterically stabilized liposomes bearing anti-HLA-DR antibodies for targeting the primary cellular reservoirs of HIV-1. Biochim. Biophys. Acta 2000; 1468(1-2): 161-74.

29. Lopes de Menezes D.E., Pilarski L.M., Belch A.R., Allen T.M. Selective targeting of immunoliposomal doxorobicin against human multiple myeloma in vitro and ex vivo. Biochim Biophys Acta 2000; 1466(1-2): 205-20.

30. Деев С.М., Лебеденко Е.М. Современные технологии создания неприродных антител для клинического применения. Acta Naturae 2001; (1): 32-50.

31. Альтшулер Е.П., Серебряная Д.В., Катруха А.Г. Получение рекомбинантных антител и способы увеличения их аффинности. Успехи биологической химии 2010; 50: 203-58.

32. Насонов Е.Л. Перспективы фармакотерапии воспалительных ревматических заболеваний: моноклональные антитела к фактору некроза опухоли-альфа. Русский медицинский журнал 2001; 9(7-8): 280-5.

33. Maini R.N., Breedveld F.C., Kalden J.R., Smolen J.S., Davis D., Macfarlane J.D., et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. 1998; 41(9): 1552-63.

34. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Fleischmann R.M., Weaver A.L., et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N. Engl. J. Med. 1997; 337(3): 141-7.

35. Dixon W.G., Symmons D.P., Lunt M. Serious infections following anti-tumor necrosis factor a therapy in patients with rheumatoid arthritis. Arthr. Rheum. 2007; 56: 2896-904.

36. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies. JAMA 2006; 295: 2275-85.

37. Schiff M., van de Putte L.B., Breedveld F.C., Kupper H., Fischkoff S., Chartash E. Rates of infection in adalimumab rheumatoid arthritis pivotal clinical trials. Ann. Rheum. Dis. 2003; 62 (suppl. 1): 184.

38. Schneeweis S., Setoguchi S., Weinblatt M., Katz J.N., Avorn J., Sax P.E., et al. Antitumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. Arthr. Rheum. 2007; 56(6): 1754-64.

39. Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum. 2004; 50(6): 1740-51.

40. Watson K.D., Dixon W.G., Hyrich KL., Lunt M., Symmons D.P., Silman A.J. Influence of anti-TNF therapy and previous malignancy on cancer incidence in patients with rheumatoid arthritis: results from the BSR biologics register. Ann. Rheum. Dis. 2006; 65: 512.

41. Chung E.S., Packer M., Lo K.H., Fasanmade A.A., Willerson J.T. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Ttherapy against congestive heart failure (ATTACH) trial. Circulation 2003; 107(25): 3133-40.

42. Ефимов Г.А., Вахрушева О.А., Сазыкин А.Ю., Муфазалов И.А., Круглов А.А., Купраш Д.В. и др. Рекомбинантные одноцепочечные антитела, блокирующие биологическую активность фактора некроза опухоли человека. Российский иммунологический журнал 2009; 3(12): 23-9.